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Card JW, Zeldin DC, Bonner JC, Nestmann ER. Pulmonary applications and
toxicity of engineered nanoparticles. Am J Physiol Lung Cell Mol Physiol 295: L400–
L411, 2008. First published July 18, 2008; doi:10.1152/ajplung.00041.2008.—Be-
cause of their unique physicochemical properties, engineered nanoparticles have
the potential to signiﬁcantly impact respiratory research and medicine by means of
improving imaging capability and drug delivery, among other applications. These
same properties, however, present potential safety concerns, and there is accumu-
lating evidence to suggest that nanoparticles may exert adverse effects on pulmo-
nary structure and function. The respiratory system is susceptible to injury resulting
from inhalation of gases, aerosols, and particles, and also from systemic delivery of
drugs, chemicals, and other compounds to the lungs via direct cardiac output to the
pulmonary arteries. As such, it is a prime target for the possible toxic effects of
engineered nanoparticles. The purpose of this article is to provide an overview of
the potential usefulness of nanoparticles and nanotechnology in respiratory research
and medicine and to highlight important issues and recent data pertaining to
nanoparticle-related pulmonary toxicity.
nanotechnology; nanomaterials; respiratory system; lung
THE POSSIBILITY OF NANOTECHNOLOGY dramatically improving the
health and quality of life of people throughout the world holds
great promise. Predictions of beneﬁcial effects of nanotechnol-
ogy in numerous industrial, consumer, and medical applica-
tions have been promising. By no means an exhaustive list,
these applications include those that may lead to more efﬁcient
water puriﬁcation, stronger and lighter building materials,
increased computing power and speed, improved generation
and conservation of energy, and new tools for the diagnosis
and treatment of disease. The optimistic outlook for a future
improved by nanotechnology must be tempered, however, by
the realization that relatively little is known about the potential
adverse effects of nanomaterials on human health and the
environment.
The deﬁnition of a nanoparticle is generally considered to be
a particle with at least one dimension of 100 nm or less. As a
result of their small size and unique physicochemical proper-
ties, the toxicological proﬁles of nanoparticles may differ
considerably from those of larger particles composed of the
same materials (15, 98). Furthermore, nanoparticles of differ-
ent materials (e.g., gold, silica, titanium, carbon nanotubes,
quantum dots) are not expected to interact with and affect
biological systems in a similar fashion. As a result, it seems
unlikely that the toxic potential and/or mechanisms of nano-
particles can be predicted or explained by any single unifying
concept.
The respiratory system represents a unique target for the
potential toxicity of nanoparticles due to the fact that in
addition to being the portal of entry for inhaled particles, it also
receives the entire cardiac output. As such, there is potential for
exposure of the lungs to nanoparticles that are introduced to the
body via the act of breathing and by any other exposure route
that may result in systemic distribution, including dermal and
gastrointestinal absorption and direct injection. Interest in the
respiratory system as a target for the potential effects, both
beneﬁcial and adverse, of nanoparticles is reﬂected by the
steady increase in the number of scientiﬁc publications on
these subjects during the past decade (Fig. 1).
The purpose of this article is to complement and expand on
previous reviews of the pulmonary effects of nanoparticles (11,
14, 34, 35) by providing an overview of potential applications
of nanotechnology in pulmonary research and in diagnosis and
treatment of disease. In addition, recent advances regarding the
potential pulmonary toxicity of nanoparticles as assessed in
human, experimental animal, and in vitro studies are discussed.
For the purposes of this article, only intentionally engineered
nanoparticles are considered; unintentionally generated (e.g.,
via combustion engines, grilling, welding) and naturally oc-
curring nanoparticles (e.g., via forest ﬁres or volcanic erup-
tions) are not included in this discussion.
NANOPARTICLES AND THE LUNG
There are myriad nanoparticles to which the respiratory
system may be exposed. There is the potential for the respira-
tory system to be exposed to a seemingly countless number of
unique nanoparticles, essentially none of which has been suf-
ﬁciently examined for potential toxicity at this time. A sub-
stantial number of nanoparticles are already present in the
marketplace in consumer products such as sunscreens, cosmet-
ics, and car wax, and many more are sure to follow (a
comprehensive list is maintained and updated by the Project on
Emerging Nanotechnologies at the Woodrow Wilson Interna-
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 tional Center for Scholars: http://www.wilsoncenter.org/nano).
Although the toxicity of the majority of nanoparticles may
prove to be minimal, the fact that there is any potential for
adverse effects to result from exposure suggests that prudence
is warranted.
Various types of nanoparticles exist including those that are
carbon-based (e.g., nanotubes, nanowires, fullerenes) and metal-
based (e.g., gold, silver, quantum dots, metal oxides such as
titanium dioxide and zinc oxide) and those that are arguably more
biological in nature (e.g., liposomes and viruses designed for gene
or drug delivery). To demonstrate the complexity of the situation,
it is worthwhile to consider the case of carbon nanotubes as an
example. Carbon nanotubes can be: 1) produced and/or cleaned
using one of several different methods; 2) produced using one
of several different metal catalysts; 3) single- or multi-walled;
4) of various lengths; and 5) subjected to numerous surface
modiﬁcations. The result of these permutations is that a vast
number of unique carbon nanotubes can be derived, all of
which fall under one broad category, namely the carbon nano-
tube. Dividing these into single-walled and multi-walled forms
reduces the ambiguity only so much, and we are still left with
potentially thousands of each type. Furthermore, as has been
demonstrated in recent in vitro experiments (37), the potential
for nanotube agglomeration or for adhesion of nanotubes to
biological molecules and the resultant alteration of their reac-
tivity must be considered. Needless to say, the variations in
nanoparticle form and functionality, not only for carbon nano-
tubes but also for nanoparticles in general, present signiﬁcant
challenges in the assessment of their potential usefulness and
toxicity.
Nanoparticle accumulation within the lung. Nanoparticles
may reach the lung via inhalation or systemic delivery and do
so by incidental/accidental or intentional means. Intentional
pulmonary administration is being examined as a means of
nanoparticle delivery for imaging and therapeutic purposes and
is discussed separately below. Incidental or accidental inhala-
tion exposure to nanoparticles can be envisioned most likely to
occur as a result of exposure to occupational aerosols during
the production or packaging of nanoparticles or nanostructured
materials (89). In addition to pulmonary effects resulting from
such exposures, translocation and subsequent systemic expo-
sure and accumulation are also possible and are being inves-
tigated. It should be noted that nanoparticles naturally tend to
agglomerate into larger particles that can be microns in size,
thereby reducing the likelihood of free nanoparticles being
respired. However, surface modiﬁcations designed to limit
particle-particle interactions and protein binding may reduce
the tendency for nanoparticle agglomeration and increase the
potential for inhalation and deposition within the lungs (131).
Incidental pulmonary exposure as a result of systemic de-
livery is likely inherent for any nanoparticle that is injected or
that might be absorbed following dermal application or inges-
tion. Although no published human data pertaining to pulmo-
nary accumulation of nanoparticles following systemic expo-
sure were identiﬁed, several animal studies have demonstrated
pulmonary accumulation of nanoparticles (or of drug-conju-
gated nanoparticles) by means of determining their quantity in
total lung homogenate preparations following their ingestion or
intravenous or subcutaneous injection (43, 71, 109, 138, 142,
155). None of these studies investigated whether systemically
administered nanoparticles traversed the blood-air barrier to
gain access to the interstitium or lung epithelium; however, this
is not necessarily a requirement for beneﬁcial (or detrimental)
effects to ensue. Although the levels and duration of accumu-
lation appear to vary for the different nanoparticles examined,
these data highlight the potential for exposure of the lungs to
nanoparticles via the systemic route.
PULMONARY APPLICATIONS OF NANOPARTICLES
Imaging and diagnostic applications. Many improvements
in imaging capabilities that will beneﬁt basic and clinical
pulmonary research and disease diagnosis can be envisioned
through the application of nanotechnology. Advances that
include the delivery of nanoparticle imaging agents to speciﬁc
cells or tissues of interest, the development of nanoprobes for
molecular imaging of disease pathways, and the development
of better contrast agents are forthcoming (21, 22, 115). Quan-
tum dots are one type of nanoparticle that is proving to be
particularly useful for imaging and diagnostic purposes. These
semiconductor nanocrystals have broad absorption spectra and
narrow emission spectra, and as their ﬂuorescence is dependent
on their chemical composition and size, multiple quantum dots
(each with a unique color emission) can be detected simulta-
neously. Moreover, their relatively large surface area provides
the opportunity for attachment of peptides or antibodies that
precisely target cell types or tissues for imaging, thereby
increasing speciﬁcity and decreasing background. In this re-
gard, Akerman et al. (2) demonstrated that quantum dots
coated with a peptide that binds to membrane dipeptidase on
pulmonary endothelial cells were detected in the lung but not
in brain or kidney 5 min after intravenous administration in
BALB/c mice. Furthermore, in a study using quantum dots
conjugated to monoclonal antibodies, rapid and speciﬁc detec-
tion of respiratory syncytial virus infection was demonstrated
in vitro and in the lungs of BALB/c mice in vivo (137).
Quantum dots have also been used to study tumor cell extrav-
asation into lung tissue in C57BL/6 mice (140), highlighting
the utility of these nanoparticles in the study of tumor metas-
tasis.
Fig. 1. Scientiﬁc publications related to the pulmonary toxicity and appli-
cations of engineered nanoparticles. The number of articles published in
each of the past 10 years was identiﬁed by searching the PubMed database
(http://www.ncbi.nlm.nih.gov/sites/entrez) using the search terms (nano-
mat* OR nanomed* OR nanopa* OR nanos* OR nanot*) AND (lung OR
airway OR alveolar OR pulmonary OR respiratory OR aerosol OR inhal*).
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 Other nanoprobes for pulmonary imaging and diagnostics
are also being examined experimentally. A recent study by le
Masne de Chermont et al. (78) demonstrated that inorganic
luminescent nanoparticles can be optically excited before in-
jection into mice to provide long-lasting imaging of the lung.
This was particularly evident for the positively charged nano-
particles that were studied, as noninvasive external detection
revealed signiﬁcant pulmonary accumulation of these nanopar-
ticles up to 1 h following intravenous injection (78).
Therapeutic applications. The potential therapeutic applica-
tions of nanoparticles in respiratory and systemic diseases are
numerous (20, 21, 112, 115, 133). A considerable thrust of
recent research has been focused on determining the suitability
of nanoparticles of various types to serve as vectors for the
pulmonary delivery of drugs or genes via inhalation or sys-
temic administration, whereas other efforts have been directed
toward developing and delivering nano-sized drug particles to
the lung (Table 1). The majority of the studies reported to date
have focused on the utility of these strategies for the treatment
of pulmonary infection. As an example, gene transfer using
intranasal administration of chitosan-DNA nanospheres was
shown to prophylactically inhibit respiratory syncytial virus
infection and to reduce allergic airway inﬂammation in mice
when given prophylactically or therapeutically (74, 75). More-
over, nanoparticle-mediated intranasal delivery of short inter-
fering RNA (siRNA) targeted against a speciﬁc viral gene,
NS1, has also been shown to inhibit respiratory syncytial virus
infection in mice and rats (72, 161).
The usefulness of nano-sized drug particles as treatment
modalities in models of pulmonary infection has also been
investigated. Inhalation of aerosolized nano-sized itraconazole
resulted in signiﬁcantly higher lung concentrations in mice
than did oral administration (138) and was found to prophy-
lactically inhibit invasive pulmonary aspergillosis and reduce
infection-related deaths in mice, whereas oral drug administra-
tion did not (4, 59). In addition, Pandey et al. (110) demon-
strated that a single inhalation of aerosolized poly (DL-lactide-
co-glycolide) nanoparticles loaded with antitubercular drugs
(isoniazid, rifampicin, or pyrazinamide) resulted in therapeutic
plasma drug levels for up to 6 days in guinea pigs and found
that repeated inhalations were as effective as more frequent
oral administrations of free drug in treating experimental tu-
berculosis. A subsequent study revealed that a single subcuta-
neous injection of these antitubercular drug-containing nano-
particles in mice resulted in therapeutic plasma drug levels for
up to 32 days and was more effective at reducing bacterial
counts in the lungs and spleen than was daily oral administra-
tion of free drug (109). Finally, Zahoor et al. (158) reported
that the same antitubercular drugs were more effective than
free oral drugs when they were encapsulated in alginate nano-
particles and administered via inhalation to guinea pigs.
Other studies relevant to the potential utility of nano-sized
drugs in disease treatment have examined siRNA-mediated
suppression of target mRNA levels following intranasal ad-
ministration of chitosan-based nanoparticles in mice (61) and
the pharmacokinetics of lipid-coated nanoparticles of 5-ﬂuoro-
uracil in hamsters (58). Moreover, allergic airway inﬂammation
in mice has been shown to be reduced by intravenous admin-
istration of polymer nanoparticles coated with a P-selectin
inhibitor (67) and by intranasal administration of chitosan
nanoparticles carrying theophylline (79). Importantly, Dames
et al. (30) recently reported on the ability to externally direct
inhaled magnetically charged iron oxide nanoparticles to spe-
ciﬁc areas of the lungs of mice without adversely affecting
respiratory mechanics, demonstrating for the ﬁrst time that
targeted aerosol delivery to the lungs is achievable. Such an
approach could prove to be beneﬁcial in the treatment of
localized lung infections or tumors.
Although the majority of the toxicity studies that are dis-
cussed below focused on nonbiodegradable nanoparticles such
as metals and carbon nanotubes, nanoparticles designed for
clinical pulmonary drug delivery will likely be biodegradable
(133). In this regard, Dailey et al. (29) reported that intratra-
cheal administration of biodegradable polymeric nanoparticles
to BALB/c mice did not induce pulmonary inﬂammation (mea-
sured as bronchoalveolar lavage ﬂuid neutrophil inﬂux, protein
content, and lactate dehydrogenase activity), whereas nonbio-
degradable polystyrene nanoparticles did. In addition to the
treatment of lung diseases, the inhalation route is being ex-
plored for the systemic delivery of drugs to treat a variety of
nonpulmonary ailments. This is due in part to the large surface
area of the lungs and the relatively high bioavailability of many
small molecules when administered by this route (113). As
discussed below, human studies have not demonstrated sys-
temic translocation of nanoparticles following inhalation, al-
though some animal studies suggest that it is possible. Indeed,
experimental animal data demonstrating achievement of ther-
apeutic plasma drug levels following inhalation of nanopar-
ticle-encapsulated antitubercular drugs (109, 110, 158) indicate
that this approach may be feasible. Efforts to develop safe and
effective nanoparticles for aerosol delivery are ongoing (33,
41, 52, 53, 124, 130) and will undoubtedly lead to signiﬁcant
advances in the treatment of respiratory and systemic diseases.
PULMONARY TOXICITY OF NANOPARTICLES
As a number of physicochemical factors can inﬂuence the
potential biological interactions and toxicity of nanoparticles, it
is important to consider the extent to which the physicochem-
ical properties of nanoparticles have been characterized in any
given study. Without sufﬁcient characterization, it is extremely
Table 1. Representative studies of pulmonary delivery
and therapeutic applications of nanoparticles in
experimental animals
Endpoint of Interest Type of Nanoparticle References
Gene delivery Polyplex 69
Silica 117
Polycation 162
Drug delivery Iron oxide 30
Lipid/5-ﬂuorouracil 58
Lipid/dexamethasone 155
Chitosan/siRNA 61
PLGA/elcatonin 157
Therapeutic effect Itraconazole 4, 59
Poly (DL-lactide-co-glycolide)/
antitubercular drugs
109, 110
Alginate/antitubercular drugs 158
Chitosan/theophylline 79
Chitosan/DNA 74, 75
Chitosan/siRNA 72, 161
siRNA, short interfering RNA; PLGA, poly(DL-lactide-co-glycolide).
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 challenging to interpret the results of individual studies and
virtually impossible to compare the results of different studies,
even in cases where the same nanoparticle has been investi-
gated. As a result, the ability to identify parameters that might
inﬂuence toxicity is hampered. Although there is not yet a
universally accepted standard set of parameters that is deemed
necessary for nanoparticle characterization, recent reports have
highlighted several key physicochemical elements for which it
is strongly recommended that data be reported (103, 143).
These include method of synthesis, size, size distribution,
shape, composition, crystal structure, aggregation and agglom-
eration status, dissolution, purity, surface area, and other sur-
face characteristics. Characterization of nanoparticles in the
context of the experimental exposure media (cell culture me-
dia, dosing solution, aerosol, etc.) is also of considerable
importance as some physicochemical parameters are likely to
differ depending on whether they are determined in the exper-
imental media or in the bulk (i.e., “as received”) state. Unfor-
tunately, the inclusion of all these parameters in publications
describing nanoparticle toxicity studies appears to be rare.
However, using these parameters as a checklist and applying
the guidance outlined in recent opinions on the matter (103,
143), the in vivo animal studies and in vitro cell culture studies
summarized in Tables 2–4 have been categorized according to
our assessment of whether or not they contain “sufﬁcient” or
“insufﬁcient” particle characterization data. The discussions of
these studies in the sections that follow focus primarily on
those considered to contain sufﬁcient information pertaining to
nanoparticle characterization, although studies that contain
insufﬁcient characterization data but nonetheless highlight im-
portant concepts are also discussed.
Studies in humans. As summarized elsewhere (7, 107),
inhaled particles of different sizes exhibit different fractional
depositions within the human respiratory tract. Although in-
haled ultraﬁne particles (100 nm) deposit in all regions,
tracheobronchial deposition is highest for particles 10 nm in
size, whereas alveolar deposition is highest for particles ap-
proximately 10–20 nm in size (7, 107). Particles 20 nm in
size also efﬁciently deposit in the nasopharyngeal-laryngeal
region. Human studies of potential adverse pulmonary effects
resulting from exposure to engineered nanoparticles appear to
be limited, although a number of investigations into pulmonary
deposition patterns of inhaled nanoparticles in the healthy and
diseased lung have been conducted (5, 24, 28, 93). Computa-
tional models predict increased deposition of inhaled nanopar-
ticles in diseased or constricted airways (44), and, consistent
with this prediction, obstructive lung disease and asthma have
both been demonstrated to increase their pulmonary retention
(5, 24). Nonetheless, Pietropaoli et al. (114) did not observe
differences between healthy and asthmatic subjects in respira-
tory parameters assessed up to 45 h after a 2-h inhalation of
ultraﬁne carbon particles (up to 25 g/m2), nor was airway
inﬂammation observed in either group (measured as exhaled
nitric oxide). Moreover, the same study reported that exposure
of healthy subjects to a higher concentration of ultraﬁne carbon
particles (50 g/m2 for 2 h) resulted in decreased midexpira-
tory ﬂow rate and carbon monoxide diffusing capacity 21 h
after exposure, albeit still in the absence of airway inﬂamma-
tion (114). Thus nanoparticles may inﬂuence respiratory func-
tion and gas exchange without a concomitant induction of
inﬂammation.
Several studies have also examined the potential for inhaled
manufactured ultraﬁne particles (i.e., 99mtechnetium-labeled
carbon nanoparticles) to translocate from the lungs to the
systemic circulation in humans. This is an important issue to
consider as inhaled engineered nanoparticles may exert adverse
cardiovascular effects, similar to the proposed mechanism for
the nanoparticulate fraction of urban air pollution (15, 40). All
but one of the studies reported to date indicate that inhaled
99mtechnetium-labeled carbon nanoparticles are not detected
outside of the lungs in appreciable quantities after inhalation
(17, 91, 93, 100, 150, 151). However, as alluded to by Mills
et al. (91), these ﬁndings do not indicate that other nanoparticles
will behave in the same manner, nor do they rule out the possi-
bility that nanoparticles may interact with and inﬂuence the
vasculature. Moreover, the studies conducted to date have used a
single inhalation exposure protocol, and it is possible that
repeated exposures may result in greater pulmonary accumu-
lation and translocation of signiﬁcant quantities of nanopar-
ticles to the circulation.
Studies in experimental animals. Pulmonary effects resulting
from airway administration of nanoparticles have been exam-
ined in a number of experimental animal studies, a summary of
which is presented in Table 2. Although the primary outcomes
of interest in the majority of these studies have been pulmonary
inﬂammation and ﬁbrosis, several have investigated distribu-
tion patterns within the lung and the potential translocation and
systemic distribution of nanoparticles following pulmonary
administration; these are summarized in Table 3. In addition to
the endpoints listed in Tables 2 and 3, carcinogenic effects of
inhaled nanoparticles (ultraﬁne particles) have, in some in-
stances, been found to be more severe than those of larger size
analogs. This is thought to result primarily from lung particle
overload due to the inability of alveolar macrophages to rec-
Table 2. Representative studies of pulmonary inﬂammation and ﬁbrosis induced by nanoparticles in experimental animals
Endpoint of Interest Type of Nanoparticle
References
Sufﬁcient Nanoparticle Characterization* Insufﬁcient Nanoparticle Characterization*
Inﬂammation and/or ﬁbrosis Carbon nanotubes 92, 99, 126, 127 23, 55, 77, 80, 87, 88, 90, 96, 146
Carbon black 6, 16, 38, 49, 132 82, 118
Fullerenes 9, 119
Silica 147 26, 42
Metals or metal oxides 12, 47, 50, 65, 108, 120, 135, 145, 148, 149 25, 36, 60, 118, 159, 160
Others 163
Modiﬁcation of inﬂammation
induced by other agents
Carbon nanotubes 126
Carbon black 3 32, 62-64
*Determined as described in the text under PULMONARY TOXICITY OF NANOPARTICLES.
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 ognize and/or clear particles of this size, leading to particle
build up, chronic inﬂammation, ﬁbrosis, and tumorigenesis.
These effects are discussed in detail elsewhere (14, 101) and
will not be covered here.
Although it is recognized that the pathogenic mechanisms
underlying animal models of lung ﬁbrosis and human lung
ﬁbrosis are not necessarily the same, increased collagen de-
position and structural changes to the lungs that can result in
altered respiratory mechanics are common features of both. As
such, for the purpose of this review, ﬁbrosis in animal models
is considered to be deﬁned by increased collagen content
and/or histopathological evidence of structural alterations to
the lung that are consistent with ﬁbrosis. With regard to
inﬂammation and ﬁbrosis, studies have focused primarily on
the effects of carbon nanotubes, carbon black, fullerenes, silica,
and metal-based nanoparticles including titanium dioxide, sil-
ver, and nickel. The reader is referred to recent reviews for
more detailed descriptions of some of the available data for
carbon nanotubes (34, 56, 76). In brief, single- and multi-
walled carbon nanotubes have been shown to induce inﬂam-
matory and ﬁbrotic responses in mice and rats following
administration by intratracheal instillation or oropharyngeal
aspiration. However, differences in the type and extent of
injury induced by the two forms of nanotubes have been
observed, and some reports indicate a lack of inﬂammation due
to carbon nanotube instillation or inhalation (88, 92). Of note,
when administered at equal doses (on a milligrams per kilo-
gram body weight basis) to mice by intratracheal instillation,
one type of single-walled carbon nanotube was found to be
more toxic than silica quartz (77), which itself poses a serious
occupational health hazard in chronic inhalation exposure sce-
narios. However, the authors of this study were unable to rule
out the possibility of nickel contamination in the nanotube
suspensions as contributing to the observed toxicity (77).
Although not the most physiologically relevant exposure
routes, instillation and aspiration have dominated pulmonary
toxicity studies of carbon nanotubes, likely due in part to their
relative ease and cost efﬁciency compared with inhalation
exposure protocols. However, concerns including the potential
formation of nanotube aggregates and how responses to these
aggregates might differ from responses to more dispersed
species necessitate caution in interpreting the available data.
Indeed, Mercer et al. (90) recently reported that the deposition
pattern and inﬂammatory/ﬁbrotic response to aspirated single-
walled carbon nanotubes in mice depended on whether the
nanotubes were dispersed before instillation. Speciﬁcally, dis-
persion was found to result in incorporation of the single-
walled carbon nanotubes into the alveolar interstitium and an
increase in collagen accumulation following aspiration admin-
istration (90), whereas the same authors had previously dem-
onstrated that nondispersed single-walled carbon nanotubes
caused a primarily granulomatous response associated with
deposition of nanotube agglomerates (127). To date, very few
inhalation exposure studies with carbon nanotubes have been
reported (80, 92). No biochemical analyses were performed in
the study by Li et al. (80), but the histopathological responses
of the lung to instilled multi-walled carbon nanotubes (0.05
mg/mouse) were compared in a nonquantitative manner to
those following inhalation of aerosols of multi-walled carbon
nanotubes for up to 15 days over the course of a 24-day period
(resulting in estimated lung burdens of 0.07, 0.14, or 0.21
mg/mouse). The authors observed considerable differences in
nanotube deposition pattern and bronchial and alveolar re-
sponses between the two administration methods. In particular,
aggregated clumps of nanotubes were evident following instil-
lation and were associated with areas of bronchial and alveolar
inﬂammation and destruction of alveoli, whereas the aerosol
inhalation exposure resulted in much less severe inﬂammation
and a general thickening of alveolar walls. Similarly, Mitchell
and colleagues (92) did not observe an inﬂammatory response
in the lungs of mice following 7 or 14 days of inhalation
exposure to multi-walled carbon nanotubes, nor did they ob-
serve any evidence of ﬁbrosis. Two important differences
between exposure via aerosol inhalation and exposure via
instillation or aspiration include the dose rate and dose distri-
bution. Both of these factors are likely to signiﬁcantly impact
the nanoparticle agglomerate state in the lungs following ex-
posure, the responses of the lung cells to the deposited mate-
rial, and the rate of translocation (if it occurs at all). Thus the
observed dissimilar ﬁndings in toxicity outcomes reported to
date highlight the importance of considering the method of
administration when assessing lung inﬂammatory and ﬁbrotic
Table 3. Representative studies of nanoparticle distribution patterns within the lung, translocation from the lung, and
systemic effects following lung administration in experimental animals
Endpoint of Interest* Type of Nanoparticle
References
Sufﬁcient Nanoparticle Characterization† Insufﬁcient Nanoparticle Characterization†
Pulmonary distribution Carbon nanotubes 19
Carbon black 125
Fullerenes 19
Metals or metal oxides 48, 95, 122
Translocation Carbon black 102, 106
Metals or metal oxides 39, 65, 73, 123, 134–136
Systemic effects Carbon nanotubes 92 83
Carbon black 49, 102
Fullerenes 9
Metals or metal oxides 65
Others 163
*Categorized as follows: pulmonary distribution, examined nanoparticle dispersion techniques or distribution patterns within the lung; translocation, examined
the potential for nanoparticles to translocate from the lung to secondary organs; systemic effects, examined effects of pulmonary administration of nanoparticles
on extrapulmonary endpoints such as peripheral cell counts, serum chemistry, cardiovascular effects, etc. †Determined as described in the text under PULMONARY
TOXICITY OF NANOPARTICLES.
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 responses to carbon nanotubes and likely to other nanoparticles
as well. This is particularly relevant given that human expo-
sures are likely to occur via inhalation of nanoparticle-contain-
ing aerosols and not by bolus instillation or aspiration of
nanoparticle-containing solutions.
Carbon black, fullerenes, silica, and metal-based nanopar-
ticles have also been studied for their ability to induce inﬂam-
matory and ﬁbrotic responses in the lungs of experimental
animals following delivery via instillation, aspiration, and/or
inhalation (Table 2). Increased lung inﬂammation resulting
from exposure to nano-sized particles compared with that
resulting from an equivalent mass of micron-sized particles has
been demonstrated in some studies (16, 45, 49, 54, 82, 118,
160), whereas others have found this not to be the case (9, 120,
135, 149). Potential factors in the increased inﬂammatory
proﬁle observed for nanoscale materials in some studies in-
clude their size, increased number, and higher surface area per
unit mass compared with that of larger particles of the same
material (15, 98, 104). Titanium dioxide is a good example of
how both the size and form of a nanoparticle can inﬂuence its
pulmonary toxicity, as a nanoscale anatase form of titanium
dioxide was found to induce greater lung inﬂammatory re-
sponses than those resulting from a nanoscale rutile form and
from a micron-sized anatase form following intratracheal ad-
ministration in rats (148). The increased ratio of surface area to
mass for nanoparticles means that a greater percentage of the
atoms or molecules of a given particle are present on the
surface of the particle, thereby providing an increased number
of potential reactive groups at the particle surface that may
inﬂuence toxicity. Although this appears to be a useful metric
for assessing the toxic potential of some nanoparticles, there is
consensus among experts in the ﬁeld that no single dose metric
(i.e., particle number, size, surface area, or other) has emerged
to be useful for assessment of the reactivity and potential
toxicity of nanoparticles in general (89, 144). Rather, it is
likely that the most appropriate means of expressing dose-
related toxicity for nanoparticles of interest will continue to be
determined on an individual basis.
Although the majority of studies have examined the pulmo-
nary effects of nanoparticles administered alone, some have
incorporated nanoparticle exposure as a potential modifying
factor in established models of airway inﬂammation (Table 2).
Carbon black nanoparticles of 14-nm size, but not of 56-nm
size, were found to exacerbate endotoxin-induced airway in-
ﬂammation in mice when given concomitantly by intratracheal
administration (62). Similarly, both 14- and 56-nm carbon
black nanoparticles promoted allergen-induced inﬂammation
in mice that was associated with increased levels of eotaxin,
TARC, MIP-1, GM-CSF, and IL-2, -5, -6, -10, and -13
protein in lung tissue (63, 64), although the exacerbating effect
was more prominent for the smaller sized particles. Enhance-
ment of allergic airway inﬂammation in mice by the intranasal
administration of carbon black nanoparticles at the time of
allergen sensitization (32) or by inhalation 24 h before allergen
challenge (3) has also been reported. Finally, Shvedova and
coworkers (126) recently demonstrated that intratracheal ad-
ministration of single-walled carbon nanotubes to mice in-
creased the inﬂammatory response to a subsequent infection
with Listeria monocytogenes and that this effect was associated
with decreased bacterial clearance and increased airway levels
of several acute phase cytokines and chemokines. Although
only two of the six studies described above contained sufﬁcient
nanoparticle characterization data (3, 126), the cumulative data
from all six studies suggest a detrimental effect of nanoparticle
exposure on airway inﬂammation induced by other agents.
As discussed earlier, studies in humans generally indicate
that inhaled manufactured ultraﬁne particles (i.e., 99mtechne-
tium-labeled carbon nanoparticles) do not translocate from the
lungs to the systemic circulation (17, 91, 93, 150, 151). A
number of studies in experimental animals have also addressed
the possibility of nanoparticle translocation from the lungs to
the circulation and extrapulmonary tissues (Table 3), some of
which indicate that certain nanoparticles may have the capacity
to do so. For example, Semmler et al. (123) observed detect-
able albeit very low levels of insoluble iridium nanoparticles in
the liver, spleen, brain, and kidney of rats following a single
inhalation exposure, whereas Ji et al. (65) reported that the
content of silver in the liver of male rats increased in a
concentration-dependent manner following inhalation of silver
nanoparticles for 5 days/wk for 4 wk. Detection of nanopar-
ticles in the liver following pulmonary delivery may not reﬂect
a direct translocation from the lungs into the bloodstream,
however, as the possibility of mucociliary transport and sub-
sequent swallowing of the nanoparticles, leading to gastroin-
testinal absorption and detectable liver accumulation, must be
considered. Also of signiﬁcant interest is the potential translo-
cation of inhaled nanoparticles to the brain via the olfactory
nerve, as has been demonstrated in rats following exposure to
inhaled nanoparticles of elemental carbon (36 nm), manganese
oxide (30 nm), and silver (12–15 nm) (39, 65, 105). Whether
such translocation to the brain has neurological or other con-
sequences remains to be determined.
There are a number of important factors that must be
considered when assessing data purporting to support direct
translocation of a nanoparticle from the lungs to the systemic
circulation and secondary organs. These include solubility,
potential leaching of a radiolabel, inﬂammation or injury in-
duced by the nanoparticle, and others. Results of rat studies
with inhaled insoluble iridium and gold nanoparticles and
soluble cadmium oxide nanoparticles offer some insight into
some of these factors. Data from studies of inhaled iridium and
gold nanoparticles, in which pulmonary inﬂammation was not
induced, indicate that translocation of these insoluble particles
from the lower respiratory tract to secondary organs accounts
for only a minute fraction of the administered dose (73, 123,
134); in the case of iridium, the vast majority was found to be
cleared via the thoracic airways to the larynx, gastrointestinal
tract, and eventually the feces (73, 123). For soluble cadmium
oxide, lung injury was reported to be the underlying cause of
translocation and accumulation in the liver following inhala-
tion as this phenomenon only occurred at a high dose at which
injury was induced and not at a low dose in the absence of
injury (135). Thus translocation to the systemic circulation can
be low even for a relatively soluble nanoparticle, indicating
that other mechanisms such as the afﬁnity of binding to cell
membranes or proteins may be important. These and other
studies reinforce the necessity to consider a variety of factors
that can inﬂuence the deposition, retention, clearance, and
translocation of nanoparticles within and from the lung.
Studies in cell culture. Studies performed to assess the
in vitro toxicity of nanoparticles can be used as part of a
screening strategy to identify potentially hazardous substances
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 and to elucidate underlying mechanisms of toxicities observed
in vivo. A considerable amount of information from in vitro (i.e.,
cell culture) analyses of the pulmonary toxicity of nanoparticles
has been published (Table 4). Related to the in vivo reports of
inﬂammation and ﬁbrosis induced by carbon nanotubes discussed
earlier, in vitro assessments indicate that nanotubes may have the
ability to induce oxidative stress and cytotoxicity in pulmonary
cells of animal and human origin, although it should be noted that
not all studies are in agreement on this matter. Indeed, metal
contaminants in nanotube preparations have been found to be
causative of some of the adverse outcomes observed in certain
in vitro investigations (68, 116), whereas anti-inﬂammatory
properties of nanotubes have been reported in others (37). In
addition, an important consideration in studies of nanotube
cytotoxicity is the means by which cell injury or death is
quantiﬁed, as nanotubes have been found to interact with some
commonly used dye-based assays and to lead to false-positive
indications of cytotoxicity (31, 153). Nonetheless, the cumu-
lative data suggest that carbon nanotubes may have the capac-
ity to induce oxidative stress and cytotoxicity in lung cells.
Studies have also been performed to assess the potential
toxic effects of nano-sized metals and metal oxides in a variety
of lung cell types in vitro (Table 4). In general, these materials
also appear to have the capacity to induce oxidative stress and
cytotoxicity, although, not surprisingly, there are apparent
differences in the extent of these effects among the different
nanoparticles studied. Furthermore, the concentrations re-
quired to induce such effects are often relatively high (i.e., in
the micrograms per milliliter range) wherein potential effects
of agglomeration should be, but are not always, considered. As
with any in vitro toxicity study, the range of concentrations
tested in nanoparticle toxicity studies should be broad so as to
allow for assessment of potentially different responses (and
underlying mechanisms) at the low and high ends of the
concentration-response curve. Moreover, similar to the inter-
ference of cytotoxicity assays by carbon nanotubes, nano-sized
metals and metal oxides may interfere with cytokine assays
commonly used to assess oxidative stress and inﬂammation
(139), thus necessitating caution in interpreting data derived
using such assays. Titanium dioxide is a commercially impor-
tant nanoparticle that has been shown to induce oxidative stress
in, among others, A549 and BEAS-2B lung cell lines (51, 84,
94). Of note, the form of nanoscale titanium dioxide appears to
be an important determinant of its cytotoxicity, as the anatase
form has been found to be more potent than the rutile form in
murine (RAW 267.9) and human (A549) lung cell lines (121,
129). These in vitro data documenting differences in cytotox-
icity due to different forms of nanoscale titanium dioxide are
generally consistent with ﬁndings in recent in vivo pulmonary
toxicity studies in rats (148).
Overall impressions from toxicity data. Several important
points related to the potential pulmonary toxicity of engineered
nanoparticles are evident in the preceding discussion of human,
experimental animal, and cell culture studies. First, as there are
currently no published human toxicity data, the potential ad-
verse pulmonary effects of engineered nanoparticles in humans
remain unknown. Although it is reasonable to assume that
nanoparticles such as carbon nanotubes and certain metal
oxides may be deleterious to the respiratory system (based on
their asbestos-like shape and the recognized toxicities of their
larger sized counterparts, respectively), the lack of reliable
predictive data indicates that established workplace safety
measures and good judgment are the best measures of protec-
tion for those most likely to encounter high level exposures.
Second, and related to the ﬁrst point, appropriate nanoparticle
characterization is key to generating meaningful data. Without
a thorough understanding of the physicochemical properties of
the nanoparticle under investigation, particularly in the rele-
Table 4. Representative in vitro studies of the pulmonary effects of nanoparticles
Endpoint of Interest Lung Cell Source Type of Nanoparticle
References
Sufﬁcient Nanoparticle Characterization* Insufﬁcient Nanoparticle Characterization*
Inﬂammation and/or oxidative stress Human Carbon nanotubes 116
Carbon black 10, 94
Silica 85
Metals or metal oxides 84, 86, 121 51, 94, 111, 139, 152
Others 18
Animal Carbon nanotubes 37 68, 116
Carbon black 154 10, 70
Silica 37
Metals or metal oxides 154 152
Others 154
Cytotoxicity Human Carbon nanotubes 153 31, 57, 116, 128
Carbon black 57, 128
Silica 85
Metals or metal oxides 86, 121 111, 128, 139, 152
Others 18, 27
Animal Carbon nanotubes 37, 153 66, 97, 116, 128, 129, 156
Carbon black 154 128, 129
Fullerenes 66
Silica 37
Metals or metal oxides 141, 154 128, 129, 152
Quantum dots 156
Others 154 156
Drug or gene delivery Human Others 1, 8, 13, 27, 46, 81
*Determined as described in the text under PULMONARY TOXICITY OF NANOPARTICLES.
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 vant exposure media, the results of any toxicity study are
descriptive at best and provide no sound basis for comparison
to other studies or for predicting potential toxicities in other
cellular or animal studies or in humans. Although less than half
of the studies summarized in Tables 2–4 provide what we feel
are sufﬁcient characterization data, a trend toward improved
nanoparticle characterization is apparent in the more recent
literature and will hopefully continue as existing testing meth-
ods are improved, new testing methods are validated, and all
become more readily available. Third, even with thorough
nanoparticle characterization, in vitro toxicities observed in
cell culture are not always predictive of in vivo pulmonary
toxicities. Good examples that support this concept are two
recent studies by Sayes and colleagues (119, 120) that reveal
very little correlation between in vitro and in vivo pulmonary
toxicities of nanoscale zinc oxide and fullerenes. These and
other studies reinforce the fact that additional time and effort
will need to be invested before reliable in vitro approaches to
predict in vivo toxicities of nanoparticles are established.
Finally, based on the preceding three points, it is suggested that
attempts to extrapolate the doses and concentrations examined
in animal models and cell culture experiments to corresponding
potential human exposure levels and toxicities are generally
ineffectual at the present time. Although it is obviously an
important goal of nanoparticle toxicity testing, the uncertain-
ties and inter-study inconsistencies that currently plague nano-
particle characterization, dose metrics, and endpoint assess-
ments make predictions of effects in humans extremely chal-
lenging.
The studies summarized in this section highlight the exten-
sive research that is being undertaken to understand the poten-
tial pulmonary toxicity of engineered nanoparticles, all with
the aim to identify adverse pulmonary effects that might occur
in humans and/or to reveal the underlying mechanisms of such
effects. Although signiﬁcant progress has been made, there is
clearly much that remains to be done. The continued evolution
of appropriate testing strategies and the cooperation and ex-
change of information among various interested parties (aca-
demia, industry, regulatory agencies, nongovernmental organi-
zations, etc.) will be crucial to realizing successful outcomes in
these important areas of research.
SUMMARY
This overview was undertaken to summarize the potential
beneﬁcial and detrimental effects of engineered nanoparticles
in the lung. As depicted in Fig. 2, a number of factors can
inﬂuence the effects of nanoparticles in the lung, most of which
have been examined to varying degrees in the studies presented
in this article. There are currently no established guidelines
for determining the potential toxicity of engineered nano-
materials in the lung or any other organ. As such, it is not
surprising that data from studies using a variety of methods,
cell types, animal models, and endpoints have been reported
in the literature, nor is it surprising that some studies are
clearly more scientiﬁcally sound than others. We chose to
present representative studies from the cumulative body of
literature pertaining to nanoparticle effects in the lung to
highlight the various avenues of research that are being
explored in this rapidly expanding ﬁeld. However, in dis-
cussing toxicity data, we attempted to maintain the focus on
data that have been generated in studies that provided
sufﬁcient detail on nanoparticle characterization, due to the
fact that such characterization is a crucial element in the
assessment of potential adverse effects of nanoparticles.
Improvements in the diagnosis and treatment of respiratory
diseases as a result of the application of nanotechnology are
anticipated, and experimental evidence indicates that engi-
neered nanoparticles have unique properties that may render
them beneﬁcial in visualizing disease processes earlier and in
delivering therapeutics to the lung, possibly even to speciﬁc
areas within the lung. Using the lungs as a portal of entry for
nanoparticles in the treatment of systemic diseases is also being
explored and holds tremendous promise. However, nanotech-
nology is not without its limitations, and of foremost concern
is the current lack of knowledge regarding the potential toxicity
of engineered nanoparticles. As has been summarized here, a
considerable amount of data from in vitro and in vivo studies
indicates that nanoparticles have the capacity to exert adverse
pulmonary effects, although not all nanoparticles are equiva-
lent in this regard. In addition, in vitro toxicities are not always
predictive of in vivo effects or potencies and vice versa,
underscoring the need for the continued development and
reﬁnement of a suitable testing strategy for assessing the
pulmonary effects of nanoparticles. It is anticipated that con-
tinued investigation into the mechanisms underlying the ad-
verse in vitro and in vivo effects summarized in this review and
their relevance to human lung physiology and disease will lead to
a better understanding of the potential hazards associated with
nanoparticle exposure and to the development of safe and effec-
tive respiratory medical applications and therapeutics based on
nanotechnology.
Fig. 2. A simpliﬁed depiction of potential factors that
may inﬂuence the effects of engineered nanoparticles
on the respiratory system.
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